Immuneering (IMRX) CFO Gengos bought 25,000 shares for $89.5K at $3.58
Immuneering (IMRX) CFO Andrew Gengos purchased 25,000 shares at $3.58 each, totaling $89.5K, on November 13, 2026. This increased his direct stake to 250,000 shares, an 11% rise. The transaction was an open-market purchase.
How this was made
The 30-second read
Why it matters
This is a sentiment datapoint for IMRX rather than a new business development. Traders may watch for follow-on insider activity or correlate with upcoming company milestones, but the article itself does not add new fundamentals.
Market read
Provides a fresh insider-buy datapoint for IMRX, which can slightly influence near-term sentiment but is unlikely to drive a major repricing alone.
What to watch
The article does not state whether the purchase was part of a pre-arranged plan, nor does it provide broader context on insider trading frequency or company-specific upcoming events.
Background
The piece summarizes an SEC Form 4 insider transaction by Immuneering’s CFO, including trade date, price, and post-transaction direct holdings.
Ticker impact
Immuneering CFO Andrew Gengos bought 25,000 shares at $3.58 on Nov 13, lifting his direct stake to 250,000 shares.
Likely mild upward bias as traders interpret the Form 4 buy as confidence, with limited follow-through absent other news.
The article reports a specific insider purchase and stake increase, which can influence short-term sentiment, but the transaction size is relatively small and no operational or guidance change is disclosed.
Market effects
Minimal sector read-through; biotech insider buys are generally low-signal without accompanying clinical or financing updates.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine compensation-related or planned diversification, so the signal may be weak versus clinical, regulatory, or financing catalysts.
Key entities
- companyImmuneering Corporation
Biotechnology company referenced as the issuer of the insider purchase.
- insiderAndrew Gengos
Immuneering CFO who reported an open-market purchase of IMRX shares.


